Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Fermentalg    FALG   FR0011271600


Delayed Quote. Delayed Euronext Paris - 07/10 11:35:14 am
1.22 EUR   -1.29%
03/31FERMENTALG : Monthly statement on outstanding equity shares and voting rights
03/27FERMENTALG : annual earnings release
2019FERMENTALG SA : quaterly earnings release
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Fermentalg : Q3 2018: Fermentalg reaches a commercial milestone for the Omega 3 range

share with twitter share with LinkedIn share with facebook
10/26/2018 | 05:50am EDT

Libourne – 18 October 2018 – Fermentalg (Euronext – FALG), a French market leader in microalgae, presents its financial results for the third quarter of 2018.

Philippe Lavielle, Fermentalg Chairman and CEO, made the following comments: “During the third quarter, we made considerable headway in developing our first platform fully dedicated to Omega 3. In just a few weeks, we signed our first sales contract with global market leader DSM and expanded our production capacity via our new manufacturing partner, ADL. In line with our commitments, DHA ORIGINS 550® is expected to start selling by the end of the year, with ramp-up already scheduled for 2019. Let me once again thank all our teams for their valiant efforts. This is a major success, but it's only the start.”

Market launch of DHA ORIGINS®

On 18 September 2018, Fermentalg announced the signing of an initial agreement with DSM Nutritional Products, a Royal DSM subsidiary, in the field of ultra-concentrated DHA oils. Under this five-year contract, Fermentalg will sell DSM its flagship product, the ORIGINS DHA 550® microalgae oil, the first algal oil with a minimum natural concentration of 550 mg/g.

By signing this agreement, Fermentalg has granted DSM Nutritional Products exclusivity limited to certain market segments. Meanwhile, Fermentalg will continue to promote its ORIGINS DHA® offering through its existing distributor network comprising IMCD in Europe, a leader in the sale, marketing and distribution of specialty chemicals and nutritional ingredients, and STAUBER, a leading US supplier of specialty ingredients.

Production of DHA ORIGINS®

In order to secure large-scale industrial capacity, on 26 September 2018 Fermentalg announced the signing of a long-term DHA algal oil production agreement with ADL BioPharma, the European specialist in industrial fermentation.

ADL BioPharma and Fermentalg plan to complete the technological approval and transfer phase by the end of 2018. Once this phase is complete, ADL BioPharma will reserve part of its fermentation capacity (total installed capacity of 2,400 m3) for Fermentalg products, ultimately allowing the Group to supply several hundred tons of DHA ORIGINS 550®.

New agreements with SUEZ to promote development of the algal biofilter

Meanwhile, Fermentalg and the SUEZ Group have signed new agreements to develop the algal biofilter (former “carbon sink”). Since 2015, the two groups have been working together to exploit the exceptional capacity of microalgae to capture CO2 from the atmosphere in urban areas and smoke emissions from industrial complexes.

Following an initial test phase that confirmed this technology's potential, Fermentalg and the SUEZ Group have signed an exclusive 8-year partnership agreement covering the technological development and industrialisation phases of the algal biofilter. A three-year marketing agreement was also signed, setting out the commercial offering for urban and industrial air purification.

Cash assets of €15.2 million at 30 September 2018

Q3 2018 revenues, that do not yet include revenues from the DSM sales contract, amounted to €117,000[1]. This figure mainly corresponds to services and initial sales of DHA oil in commercial launch and sample volumes.

At 30 September, gross cash amounted to €15.2 million, down from €17.4 million at 30 June 2018 but in line with cash burn recorded in the first half.

About Fermentalg:

An expert in research and bio-industrial use of microalgae, Fermentalg seeks to provide sustainable solutions and innovative products that contribute towards the creation of natural, healthy and effective products. Our business: the development, production and sale of active ingredients extracted from microalgae for the health and nutrition sectors. Natural nutritional oils, pigments and antioxidants, as well as specialty proteins, comprise our present and future offering.

Fermentalg shares are listed on Euronext in Paris (FR0011271600 - FALG).

For more information, visit: www.fermentalg.com



Contact - Journalists: Contact - Investors:
ACTUS finance & communication
Alexandra PRISA
Tel: +33 (0)1 53 67 36 90
ACTUS finance & communication
Tel: +33 (0)1 53 67 36 78



[1] No income was recorded in Q3 2017.

Regulated information
Quaterly financial disclosure:
- Third Quarter Information
Full and original press release in PDF:
Receive by email the next press releases of the company by registering on www.actusnews.com, it′s free

© 2018 ActusNews
share with twitter share with LinkedIn share with facebook
Latest news on FERMENTALG
03/31FERMENTALG : Monthly statement on outstanding equity shares and voting rights
03/27FERMENTALG : annual earnings release
2019FERMENTALG SA : quaterly earnings release
2019FERMENTALG : New independent director appointed to Fermentalg’s Board of Directo..
2019FERMENTALG : Nomination
2019FERMENTALG : 2018 overview: Successful market launch of premium Omega 3
2018FERMENTALG : Fermentalg included in Kepler Cheuvreux survey
2018FERMENTALG : Q3 2018: Fermentalg reaches a commercial milestone for the Omega 3 ..
2018FERMENTALG : Fermentalg moves to the next phase in its partnership with the SUEZ..
2018FERMENTALG : Fermentalg and ADL Biopharma announce a toll manufacturing alliance..
More news
Sales 2020 3,54 M 4,00 M 4,00 M
Net income 2020 -5,10 M -5,76 M -5,76 M
Net Debt 2020 19,9 M 22,5 M 22,5 M
P/E ratio 2020 -3,28x
Yield 2020 -
Capitalization 25,7 M 29,1 M 29,1 M
EV / Sales 2019
EV / Sales 2020 12,9x
Nbr of Employees 65
Free-Float 97,3%
Duration : Period :
Fermentalg Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FERMENTALG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Average target price 2,85 €
Last Close Price 1,22 €
Spread / Highest target 195%
Spread / Average Target 134%
Spread / Lowest Target 72,1%
EPS Revisions
Philippe Lavielle Chairman & Chief Executive Officer
Bertrand Devillers Chief Financial Officer
Hywel Griffiths Chief Scientific Officer
Stéphane Villecroze Director
Gilles Schang Director
Sector and Competitors
1st jan.Capitalization (M$)
ECOLAB INC.3.97%57 093
HENKEL AG & CO. KGAA-9.46%38 069
GIVAUDAN19.50%35 516
SIKA AG4.81%28 737